The global nonstructural protein 4B market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Nonstructural protein 4B (NS4B) induces the specific membrane alteration and is elected as a membranous web (MW). It is an integral membrane protein that is predicted to comprise four transmembrane segments in its central part. The major factor contributing to the growth of the market is the increasing prevalence of hepatitis across the globe. 

According to World Health Organization (WHO), in 2021, an estimated 58 million people have chronic hepatitis C virus infection globally. Additionally, an estimated 1.5 million new infections occur every year.  Furthermore, approximately 290,000 people died from hepatitis C mostly due to cirrhosis and hepatocellular carcinoma (primary liver cancer) in 2019. Moreover, over 95% of persons with hepatitis C infection are cured by antiviral medicines. Hence, the rising prevalence of the disease is driving the demand for nonstructural protein 4Bs for the treatment which in turn is driving the growth of the market. 

Some major players in the market include Gilead Sciences, Inc., Johnson and Johnson Services, Inc., and AbbVie Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2019, AbbVie announced that it has received FDA approval for Mavyret (Glecaprevir/Pibrentasvir). It is used to shorten the treatment duration to eight weeks for the treatment of patients with chronic hepatitis c and compensated cirrhosis across all genotypes

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Gilead Sciences, Inc., Johnson and Johnson Services, Inc., and AbbVie Inc., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Nonstructural Protein 4B Market Report by Segment

By Type

    • INO-8000

    • GSK-8853

    • PTC-725

    • RL-15A

    • Others

By Application

    • Hospital 

    • Clinics

    • Others

Global Nonstructural Protein 4B Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa